Richard B. Lanman

This article is about Richard B. Lanman, Biotechnology Entrepreneur. For Richard B. Lanman, Technology Entrepreneur, see Fritz Lanman.
Dr. Rick Lanman
Dr. Lanman at his home in 2023
Born
Richard Burnham Lanman Jr.

1955 (age 68–69)
Frankfurt am Main, Hesse, Germany
NationalityAmerican
EducationStanford University, B.S. 1977
Northwestern University School of Medicine, M.D. 1980
Occupation(s)Physician-scientist and Naturalist
Years active1978-present
Known forBiomarkers in Cardiovascular disease and Cancer, and Historical ecology
RelativesMartha Lee Hopkins Struever (mother)
Fritz Lanman (son)
James Lanman (son)
Medical career
ProfessionMedical Doctor
InstitutionsGuardant Health, Inc.
Veracyte, Inc.
diaDexus, Inc.
Atherotech, Inc.
San Jose Medical Group, Inc.
Kaiser Permanente
ResearchCancer genomics, Precision oncology, Cardiovascular Biomarkers, Thyroid cancer, Interstitial lung disease, Psychiatry, Ecology

Richard Burnham Lanman is an American biotechnology entrepreneur, physician scientist, and naturalist.[1] His contributions relate to improving diagnosis and utilization of less invasive medical procedures,[2][3] most recently as Global Chief Medical Officer at Guardant Health, Inc., a precision oncology company that developed a blood test replacing invasive tissue biopsies to sequence tumor DNA and improve cancer treatment selection.[4][5][6] Lanman has worked in five different medical specialties, oncology, cardiology, endocrinology, pulmonology, and psychiatry, as well as historical ecology, and has authored or co-authored 130 peer-reviewed scientific publications.[7]

  1. ^ Ben Goldfarb (2018). Eager: The Surprising, Secret Life of Beavers and Why They Matter. Chelsea Green Publishing. pp. 135–141. ISBN 9781603587402. Retrieved January 6, 2019.
  2. ^ L. Page (May 15, 2000). "Fee for Episode". American Medical News. pp. 13–14.
  3. ^ Lanman R (1994). Horn SD; Hopkins DSP (eds.). Improving Pediatric Asthma Care in a Health Maintenance Organization, in Clinical Practice Improvement: A New Technology for Developing Cost-Effective Quality Health Care. New York: Faulkner & Gray, Inc. pp. 169–174. ISBN 9781881393252.
  4. ^ João Medeiros (February 5, 2017). "Marcus Krause's lung cancer wouldn't stop growing. Then he took a new kind of blood test". Wired UK. Retrieved February 1, 2020.
  5. ^ Richard Harris (December 16, 2016). "When Genetic Tests Disagree About Best Option For Cancer Treatment". National Public Radio (NPR). Retrieved February 3, 2020.
  6. ^ Anna Czene (December 11, 2019). "Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing". Barron's. Retrieved February 20, 2020.
  7. ^ "PubMed Single Citation Matcher". National Library of Medicine National Center for Biotechnology Information. Retrieved April 14, 2022.